Shares of C3.ai Inc. AI slipped 6.06% to $22.03 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.76% to 5,849.72 and Dow ...

C3.ai, Inc. (AI) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

I t's understandable why so many automakers have moved away from selling no-frills cars. Profit margins are smaller when ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

C3.ai (NYSE:AI – Free Report) had its price objective lowered by DA Davidson from $40.00 to $25.00 in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a ...

Needham & Company LLC reiterated their hold rating on shares of C3.ai (NYSE:AI – Free Report) in a research note issued to investors on Thursday morning,Benzinga reports. Other research analysts have ...

Tmall Magic Screen C3 Air projector debuts with 1080P resolution, a built-in clock, a 360° adjustable stand, and an SSD2381 chip.

Feb. 27 at approximately 6:35 p.m., members of the Springfield Police C3 Units seized a loaded firearm and arrested ...

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Shares of C3.ai Inc. AI slipped 1.80% to $23.45 Friday, on what proved to be an all-around positive trading session for the ...

Bullish sentiment in the capesize spot market has continued this week, with rates approaching their highest level in almost ...

A new study highlights the importance of normal serology in reducing severe and renal flares in systemic lupus erythematosus ...